Effect of the Angiotensin II Receptor Antagonist Telmisartan on Lipoprotein Lipase Mass in Preheparin Serum

Hatori, Takashi; Takahashi, Mitsuru; Iizuka, Takuo; Shirai, Kohji

doi:10.5551/jat.e547

Cited by 10 publications

(7 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our present results indicate that the hypolipidemic effect of telmisartan might also be mediated by increased expression of LPL. Interestingly, treatment of hypertensive patients with telmisartan increases serum LPL mass, and this is associated with a decrease in risk factors for coronary events (40).…”

Section: Discussionmentioning

confidence: 99%

Telmisartan increases lipoprotein lipase expression via peroxisome proliferator-activated receptor-alpha in HepG2 cells

et al. 2013

View full text Add to dashboard Cite

In addition to their hypotensive properties, angiotensin receptor blockers (ARBs) have been shown to exert clinical antidyslipidemic effects. The mechanism underlying these ARB lipid metabolic effects remains unclear. Some ARBs, for example, telmisartan, activate peroxisome proliferator-activated activated receptor-gamma (PPAR-gamma). We hypothesized that PPAR-gamma-activating ARBs might exert antidyslipidemic effects via PPAR-alpha. In this study, we assessed the effect of telmisartan on the expression of PPAR-alpha and lipoprotein lipase (LPL). PPAR-alpha expression was detected by reverse-transcription polymerase chain reaction and Western blot in HepG2 hepatocytes as well as differentiated C2C12 myocytes treated with increasing concentrations of telmisartan (0.1-10 μmol/L) for 48 h. Results showed that 1 μmol/L and 10 μmol/L telmisartan significantly increased the expression of PPAR-alpha mRNA and protein in HepG2 cells (p < 0.01). No effect was shown in differentiated C2C12 cells. Similarly, 1 µmol/L and 10 μmol/L telmisartan significantly increased the expression of LPL mRNA and protein in HepG2 cells (p < 0.01), and this increase was significantly (p < 0.01) inhibited by the PPAR-alpha-specific antagonist MK886. These results indicate that certain of the antidyslipidemic effects of telmisartan might be mediated via increased PPAR-alpha-dependent induction of LPL expression.

show abstract

Section: Discussionmentioning

confidence: 99%

Telmisartan increases lipoprotein lipase expression via peroxisome proliferator-activated receptor-alpha in HepG2 cells

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Clinical studies have suggested that treatment with pioglitazone in T2D subjects significantly increases lipoprotein lipase mass in preheparin serum (LPL mass) 10) . LPL mass reflects lipoprotein lipase (LPL) production from adipocytes 11) , and is a marker of insulin sensitivity [12][13][14][15][16][17] . Our in vitro study has shown that A inhibits adipogenic differentiation of 3T3-L1 cells, and the inhibitory effect is reversed by pioglitazone 18) .…”

Section: Introductionmentioning

confidence: 99%

Pioglitazone Decreases Plasma Angiotensin II Concentration inType 2 Diabetes

Saiki

Ohira

Endo

et al. 2010

JAT

Self Cite

View full text Add to dashboard Cite

Aim:Adipocytes express all components of the renin-angiotensin system (RAS), and adipocyte RAS regulates adipocyte differentiation and metabolism. Plasma angiotensin (A ) is a putative marker of adipocyte RAS production. The aim of this study was to investigate the effect of pioglitazone on plasma A in type 2 diabetes (T2D). Methods: Fifty Japanese subjects with T2D were randomly allocated to two groups. One group was administered pioglitazone 30 mg/day (pioglitazone group) and the other group was not given pioglitazone (control group) for 16 weeks. Lipoprotein lipase mass in preheparin serum (LPL mass) was measured as an adipocyte-derived factor and a marker of insulin sensitivity. Results: In the pioglitazone group, the mean HbA1c decreased ( p 0.0001), LPL mass increased ( p 0.0001), and plasma A decreased ( p 0.0007), whereas these parameters were unchanged in the control group. The change in plasma A correlated negatively with the change in LPL mass (r 0.312) in the pioglitazone group. In the pioglitazone group, the decrease in plasma A was higher ( p 0.0002) and the increase in LPL mass tended to be higher ( p 0.0941) in the subgroup with higher baseline plasma A than that with lower plasma A . Conclusions: The present study indicates that pioglitazone decreases plasma A associated with an increase in LPL mass in T2D. The insulin-sensitizing effect of pioglitazone may be involved in suppressing adipocyte RAS. J Atheroscler Thromb, 2010; 17:651-657.

show abstract

“…Several studies have reported that antihyperlipidemic agents [41][42][43][44] , angiotensin receptor blockade therapy [45][46][47] , and thiazolidinedines 13,14) significantly increase both s-LpL and blood adiponectin concentrations. These drugs have been confirmed to be clinically useful for preventing primary and secondary cardiac events [48][49][50] ; thus, it is possible that these protective effects towards coronary vessels are caused by increased s-LpL or blood adiponectin concentrations.…”

Section: Discussionmentioning

confidence: 99%

Relationship between Two AMI Risk Factors: Low Serum Lipoprotein Lipase Mass and Hypoadiponectinemia

Hatori

Takahashi

Iizuka

et al. 2011

JAT

Self Cite

View full text Add to dashboard Cite

Aim: Recent clinical studies have reported that low lipoprotein lipase mass in preheparin serum (s-LpL) and hypoadiponectinemia are important risk factors for acute myocardial infarction (AMI). The aim of this study was to elucidate the relationship between low s-LpL and hypoadiponectinemia, both of which are risk factors for AMI. Methods: One hundred and thirty-seven male patients with AMI and fifty-three males with normal coronary arteries (NCA) were enrolled in the study. Coronary risk factors, including s-LpL and serum total adiponectin concentrations (t-adiponectin), were compared. Results: Both s-LpL and t-adiponectin were significantly lower in patients with AMI than in subjects with NCA (s-LpL, NCA: 48.1 11.0 ng/mL, AMI: 38.9 11.1 ng/mL, p 0.01; t-adiponectin, NCA: 7.7 2.9 g/mL, AMI: 6.

show abstract

Effect of the Angiotensin II Receptor Antagonist Telmisartan on Lipoprotein Lipase Mass in Preheparin Serum

Cited by 10 publications

References 58 publications

Telmisartan increases lipoprotein lipase expression via peroxisome proliferator-activated receptor-alpha in HepG2 cells

Telmisartan increases lipoprotein lipase expression via peroxisome proliferator-activated receptor-alpha in HepG2 cells

Pioglitazone Decreases Plasma Angiotensin II Concentration inType 2 Diabetes

Relationship between Two AMI Risk Factors: Low Serum Lipoprotein Lipase Mass and Hypoadiponectinemia

Contact Info

Product

Resources

About